Targeting benign prostate hyperplasia treatments: AR/TGF-β/NOX4 inhibition by apocynin suppresses inflammation and proliferation

Targeting benign prostate hyperplasia treatments: AR/TGF-β/NOX4 inhibition by apocynin suppresses inflammation and proliferation

Introduction: Apocynin (Apo), an NADPH oxidase (NOX) inhibitor, has been widely used to treat various inflammatory diseases. However, the therapeutic effects of Apo on benign prostatic hyperplasia (BPH), a multifactorial disease associated with chronic inflammation and hormone imbalance, remain unkn...

Full description

Bibliographic Details
Main Authors: Bo-Ram Jin, Hyo-Jung Kim, Jung-Hyun Na, Won-Kyu Lee, Hyo-Jin An
Format: Article
Language:English
Published: Elsevier 2024-03-01
Series:Journal of Advanced Research
Subjects:
Apocynin, Androgen receptor
Benign prostatic hyperplasia
Dihydrotestosterone
NOX4
Prostate cancer prevention
Online Access:http://www.sciencedirect.com/science/article/pii/S2090123223001121

Internet

http://www.sciencedirect.com/science/article/pii/S2090123223001121

Similar Items